Paediatric Cushing’s disease — a literature review of epidemiology, pathogenesis, clinical symptoms, and diagnostics by Pasternak-Pietrzak, Katarzyna et al.
87
Review (postgRaduate education)
R
E
V
IE
W
Paediatric Cushing’s disease — a literature review 
of epidemiology, pathogenesis, clinical symptoms, 
and diagnostics
Katarzyna Pasternak-Pietrzak1, Elżbieta Moszczyńska1, Elżbieta Jurkiewicz2, Mieczysław Szalecki1, 3
1Department of Endocrinology and Diabetology, The Children’s Memorial Health Institute, Warsaw, Poland
2Department of Radiology, The Children’s Memorial Health Institute, Warsaw, Poland
3Collegium Medicum of Jan Kochanowski University, Kielce, Poland
Abstract 
Cushing’s disease (CD) is characterised by excess production of adrenocorticotropic hormone (ACTH) by a pituitary corticotroph ad-
enoma, which results in hypercortisolaemia. CD is extremely rare in the paediatric population, and few paediatric endocrinology centres 
have experience in diagnosing and treating this disease. The clinical presentation of hypercortisolaemia is variable, so proper and rapid 
diagnosis of CD is often challenging. The molecular pathogenesis of CD was largely unknown until recently. The latest research has 
revealed somatic mutations in the USP8 gene as the most common pathogenic molecular variants of this disease. Herein, we describe 
the current state of knowledge of paediatric CD epidemiology, molecular pathogenesis, clinical symptoms, and diagnostics. (Endokrynol 
Pol 2020; 71 (1): 87–95)
Key words: Cushing’s disease; pituitary adenoma; hypercortisolaemia; Cushing’s syndrome; growth retardation; weight gain
Introduction
Cushing’s disease (CD) is defined as a state of hypercor-
tisolaemia caused by excessive secretion of adrenocorti-
cotropic hormone (ACTH) by a pituitary corticotroph 
adenoma. Cushing’s disease is characterised by an in-
creased risk of cardiovascular, metabolic, psychiatric, and 
infectious diseases [1]. Because of an increased mortality 
ratio in the case of persistent disease, CD has become 
a diagnostic and therapeutic challenge for physicians [2]. 
Epidemiology
While the incidence rate of Cushing’s syndrome (CS) is 
1.89–2.3/mln/year in Danish patients [3], 2–5/mln/year 
in the Spanish population [4], and 39.5–48.6/mln/year 
in the US population aged ≤ 65 years [5], the incidence 
rate of CD in these populations is reported to be, re-
spectively: 1.2–1.7/mln/year [3], 0.7–2.4/mln/year [4], 
and 6.2–7.6/mln/year [5]. It should be noted that only 
10% of new cases occur in children [6].
Cushing’s disease is the most common cause of 
endogenous CS, especially in children over five years 
of age [7–9]. It accounts for 75-80% of paediatric CS 
cases (for comparison, 49–71% of adult cases) [7, 10]. 
In children under five years of age CD occurs rarely 
— the most common causes of CS in this age group 
are adrenal lesions: adenoma, carcinoma, or bilateral 
adrenal hyperplasia [6, 11]. According to Kunwar et al. 
[12], pituitary corticotroph adenomas constitute 54.8% 
of all pituitary adenomas in the age group 0–11 years 
and 29.44% in the age group 12–17 years. The mean 
age of CD presentation (on the basis of large studies on 
the paediatric population; groups of 41–182 children) 
is 12.3–14.1 years [13–15].
However, CD has a female preponderance in adults 
(with an overall prevalence of 79%), in children a male 
preponderance has been documented, with an overall 
prevalence of 63% [8, 14, 16]. 
According to the study by Lubuit et al., boys may 
have more aggressive disease with an elevated body 
mass index, shorter height, and higher ACTH levels, 
in comparison with girls [17].
Molecular pathogenesis
The pathogenesis of CD is not fully understood. Stud-
ies on the molecular basis of pituitary adenomas have 
been the goal of many researchers in recent years. It is 
known that mutations in genes that cause syndromes 
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nostic process can reveal irregularities such as: puberty 
disorders, hypertension, and carbohydrate metabolism 
disorders. 
Regarding puberty disorders, menstrual irregulari-
ties, amenorrhoea, and premature or delayed sexual 
development may be diagnosed. Young children may 
present with premature sexual development, acceler-
ated epiphyseal maturation, and virilisation (as a result 
of increased adrenal androgen secretion), whereas older 
children and adolescents may have delayed puberty (as 
a result of glucocorticoid-induced hypogonadism) [8, 
33]. Dupuis et al. in their analysis of 27 children with CD 
concluded that many patients had abnormal puberty 
and excessive virilisation associated with increased 
adrenal androgens, while pubertal patients had low go-
nadotropin concentrations, which suggested impaired 
pituitary–gonadal axis function [33].
Hypercortisolaemia, in addition to a number of 
other symptoms, also affects mood changes and may 
cause mental disorders (including emotional lability, 
irritability, or depression), but these problems are less 
frequently seen in children in comparison to adults 
[34]. Muscular atrophy and sleep disturbances are also 
rarely seen in children.
The mean length of symptoms prior to diagnosis 
reported in the literature is from 1.8 years (range 0.5–3.5) 
in the study by Yordanova et al. (21 children with CD), 
2.33 years (range 0.25–7) in the study by Batista et al. 
(72 children with CD), 2.5 ± 1.7 years (range 0.3–6.6) 
in the study by Savage et al. (37 children with CD), to 
3 ± 2 years (range: 3 months –7 years) in the study by 
associated with pituitary adenomas: multiple endocrine 
neoplasia type 1 (MEN1), multiple endocrine neopla-
sia type 4 (CDKN1B), McCune-Albright syndrome 
(GNAS1), familial isolated pituitary adenoma (AIP), 
and many more (CABLES1, DICER1, MC2R PRKAR1A, 
PRKACA, RAF1, TP53) occur sporadically and account 
for only a small portion of CD cases [18–23]. Somatic 
mutations in the gene USP8 encoding the ubiquitin-spe-
cific protease 8 have been detected recently as the 
most common alterations in patients with CD (found 
in 31–63% of corticotroph adenomas) [15, 24–27]. The 
ubiquitin-specific protease 8 inhibits the lysosomal 
degradation of the epidermal growth factor receptor 
(EGFR) [28]. As a result of the gain-of-function somatic 
mutation, the binding of the inhibitory 14-3-3 proteins 
to the ubiquitin-specific protease 8 is impaired, which 
results in increased deubiquitination of EGFR and 
induction of proopiomelanocortin transcription and 
ACTH secretion [25] (Fig. 1).
Clinical presentation
The rarity of CD occurrence in children poses a risk 
of being overlooked in everyday clinical practice. The 
principal features of CD in children are: weight gain 
and growth failure [13, 29–32]. Facial changes (facial 
rounding/moon facies), headaches, and hirsutism are 
also typical clinical features (Fig. 2). 
Skin manifestations in CD: acne, facial plethora, 
violaceous striae, bruises and hyperpigmentation can 
be present but none of them is a key feature. The diag-
Figure 1. Schematic representation showing the proposed mechanisms how USP8 mutations lead to increased ACTH secretion and 
tumorigenesis in corticotroph, according to Reincke 2015, with permission [25]
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Magiakou et al. (50 children with CD) [8, 29, 31, 35, 36]. 
Early recognition of CD key features is necessary to 
allow quick diagnosis and effective therapy.
The analysis of clinical features of patients from 
a few groups (17–200 children) presented in a few stud-
ies is shown in Table 1.
Evaluation of Cushing’s syndrome
Interview and clinical evaluation, especially growth 
data, are key in the initial diagnosis of CD [37]. Bio-
chemical evaluation and imaging are the basis of CD 
diagnosis. Before biochemical evaluation the use of 
exogenous corticosteroids should be excluded (gluco-
corticoids applied orally, intranasally, topical treatments 
or inhalers) as the most common reason of CS [38].
Confirmation of hypercortisolaemia
The first step of diagnostics in the direction of CS is the 
confirmation of hypercortisolaemia, which should take 
place in the ambulatory care [39].
The 1-mg overnight dexamethasone suppression test
The 1-mg overnight dexamethasone suppression 
test is done by administering to the patient 1 mg of 
dexamethasone (Dx) orally in the evening at 23:00 (or 
between 23:00 and midnight) [40] and measuring the 
serum cortisol concentration the next morning at 08:00 
(or between 08:00 and 09:00) [39]. The cortisol concen-
tration > 1.8 μg/dL (with the sensitivity 95% [41] and 
specificity 80% [42]) commits to further diagnostics in 
the direction of CS [43]. The percentage of false nega-
tives is low (which means that false-normal suppression 
is rarely detected), and the percentage of false positive 
results is 15–20% [37].
Two studies in woman [44, 45] have potentially 
led to increased cortisol results by contraceptives. Al-
though the 1-mg overnight Dx suppression test is used 
as a screening test for paediatric patients, there are 
lacking data on its interpretation or reliability in this 
population.
It is also important to remember about other drugs 
that can interfere with the evaluation tests for the 
diagnosis of CS: drugs that accelerate Dx metabolism 
by induction of CYP 3A4 (e.g. phenobarbital, carbam-
azepine, and others), drugs that impair Dx metabolism 
by inhibition of CYP34A (e.g. itraconazole, fluoxetine), 
drugs that increase cortisol-binding globulin (CBG) and 
may falsely elevate cortisol results (e.g. mitotane), and 
drugs that increase urinary free cortisol (UFC) results 
(e.g. carbamazepine, fenofibrate) [43].
24-h urinary free cortisol excretion
24-h UFC excretion is a good screening test for hyper-
cortisolism and gives information about unbound cor-
tisol, which is not affected by factors influencing CBG 
[46]. The result should be corrected for the child’s body 
surface area [37]. 24-hour urine should be collected for 
three consecutive days to exclude cyclic CS with a high 
probability.
According to Reimondo et al., the diagnostic cut-off 
value of 24-h UFC (with 100% sensitivity) is > 38 mg/24 h 
[47]. Sensitivity of this test for CD analysed by Batista et 
al. in their study of 105 children with CS was 88% and 
Figure 2. A. Clinical presentation of a 5-year-old male with CD. Note plethora and mooning of face. B. Clinical presentation of a 
10-year-old male with CD. Note acanthosis nigricans. C. Clinical presentation of a 16-year-old female with CD. Note acne. D. Clinical 
presentation of a 16-year-old female with CD. Note stretch marks
A
C
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specificity was 90%, which means that 24-h UFC alone 
is not an ideal test in screening for CS [39].
Falsely high UFC (pseudo-Cushing syndrome) can 
be obtained in the following states: physical activity, 
stress, anxiety, depression, anorexia, pregnancy, se-
vere obesity, alcoholism, malnutrition, and high water 
intake [37]. 
Normal results in both 1-mg overnight Dx suppres-
sion test and 24-h UFC exclude CS in 90–95% of cases 
(in 5–10% the disease has intermittent or cyclic course 
or does not manifest in any test) [37].
Cortisol circadian rhythm
It is recommended that cortisol circadian rhythm is 
performed in a hospital setting. A venous sampling 
catheter should be inserted at least two hours before 
the test. Time points in which cortisol should be 
measured vary depending on the centre. Batista et 
al. (the National Institute of Health, Bethesda, USA) 
suggest measuring cortisol levels at 23:00 and 24:00 
and at 07:30 and 08:00 [38]. Storr et al. recommends 
measuring serum cortisol level at three time points: 
09:00, 18:00, and midnight (sleeping: 24:00) [48]. Late 
night salivary cortisol has the highest sensitivity and 
specificity (also in the obese population) — according 
to Batista analysis: 99% and 100% [39]. The diagnostic 
cut-off value of midnight cortisol is > 1.8 mg/dL (50 
nmol/L) [49]. If a patient is awakened at night, blood 
should be collected within five minutes of awakening 
[50]. Then, the sensitivity and specificity of a midnight 
serum cortisol level > 7.5 mg/dL in an awake patient is 
reported to be > 96% [51].
Low-dose dexamethasone suppression test
A low-dose dexamethasone suppression test (LDDST) 
is performed with the dose regimen for adults (unless 
the child weighs < 40 kg): 0.5 mg every 6 h (at 09:00, 
15:00, 21:00, and 03:00) for 48 h. If the child weighs < 40 
kg, the dose is 30 μg/kg per dose, max. 0.5 mg/dose 
[8]. The National Institute of Health in Bethesda sug-
Table 1. The analysis of clinical features at diagnosis of Cushing’s disease on the basis of published data [14, 29, 31, 32, 35, 36]
Clinical feature
Percentage of patients (%)
Storr 2011  
(41 children)
Devoe 1994  
(42 children)
Yordanova 2016 
(21 children)
Batista 2009 
(72 children)
Savage 2001 
(17 children)
Lonser 2013 
(200 children)
Weight gain 98 92 100 62a 100 93 (71a)
Growth retardation 84 95 82b 71 63c
Facial changes 100 46d 100 63e
Irregular menses (females) 73 49f
Osteopaenia 74 30
Fatigue 61 67 62 41 59 48
Hirsutism 59 46 52 39 53 56
Psychiatric disorders 59g 44h 71g (5i; 5j) 28g 41g 31g
Headaches 51 26 52 33 38
Striae 49 36 43 40k 53 55k
Hypertension 49 63 43 46 75 36
Acne 44 46 38 46 41 47
Pubertal delay or arrest 60 7
Easy bruising 28 22 25
Dorsal cervical or 
supraclavicular fat pad 28
l 69
Acanthosis nigricans 26 32
Muscle weakness 13
Sleep disturbances 11
Glucose intolerance or 
diabetes 7
Bone fractures 5 4
aobesity (body mass index Z-score > 2.0); bshort stature; cdecreased linear growth [significantly different (Fisher’s exact test, p < .01)]; dplethora; emoon facies; 
famenorrhoea (primary or secondary); gdepression, anxiety, mood swings; hcompulsive behaviour; ianxiety combined with challenging behaviour; jacute psychosis; 
khyperpigmented abdominal striae; lBuffalo hump; mvertebral fractures due to severe osteoporosis
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gests adjusting the dose according to the weight for 
children weighing < 70 kg by dividing the dose by 70 
and multiplying by the weight of the child [6]. Urine is 
collected for 24-h UFC for two consecutive days before 
Dx administration and on the second day of Dx admin-
istration [34]. Serum cortisol is measured at 0, 24, and 
48 h. UFC < 10 μg/d 48 h after Dx administration and 
serum cortisol level < 1.8 μg/dL are a normal response 
[34]. Serum cortisol values < 1.8 μg/dL (measured after 
48 h) exclude CS with 97–100% sensitivity [39, 49].
Confirmation of Cushing’s syndrome
Once CS is diagnosed, the next step is to distinguish 
ACTH-dependent disease from the ACTH-independent 
syndrome. 
Basal plasma ACTH
As hypercortisolaemia leads to corticotropin (CRH) 
and ACTH suppression from healthy corticotroph 
cells, measurement of plasma ACTH differences in 
ACTH-dependent and ACTH-independent CS: in CD 
ACTH is always detectable; in ACTH-independent 
CS ACTH is low and usually undetectable [11, 34, 51]. 
According to Batista et al., the diagnostic cut-off value 
for CD is ACTH level >29 ng/L — the sensitivity and 
specificity above this value are documented as, respec-
tively, 70 and 100% [39].
Pecori Giraldi et al. emphasise that many com-
mercially available ACTH assays are imprecise in the 
low ranges, and the result should be interpreted with 
caution [52]. Moreover, single measurements of cortisol 
and ACTH are not of great value in diagnosis because 
of their circadian nature [37].
High-dose dexamethasone suppression test
Classic high-dose dexamethasone suppression test 
(HDDST, Liddle test) is used to differentiate CD from 
ectopic ACTH secretion and adrenal causes of CS [37]. 
In brief, after LDDST as described above, a high dose 
of Dx (120 μg/kg/dose; max 2 mg/dose) is given per os 
every six hours for two days [6]. A single high dose of 
Dx (in children < 70 kg adjusted for weight as described 
above, max 8 mg) can be also given at 23:00, and the 
plasma cortisol level is measured the following morning 
(sensitivity and specificity are similar to classic Liddle 
test). Urine is collected for 24-h UFC as described in 
LDDST and on the second day of high dose of Dx 
administration. Cortisol is measured at 09:00 the day 
after Dx administration. A 50% suppression of serum 
cortisol levels from baseline differentiates CD (> 50% 
suppression) from other causes of CS (adrenal or ectopic 
ACTH production) (< 50% suppression) [6]. 
Approximately 85% of patients with CD will have 
suppression of serum cortisol, UFC, and 17-hydroxys-
teroid values, and less than 10% of patients with ectopic 
ACTH secretion will have suppression [37].
Stratakis C.A. [37] in his article indicates situations 
when the classic Liddle test is preferred rather than 
a modified overnight HDDST: 1) non-suppression of 
serum cortisol levels during the HDDST; 2) negative 
imaging studies; 3) suspected adrenal disease.
CRH test
The ovine (o)CRH test has equal or even greater diag-
nostic value than HDDST in differentiating between 
CD and ectopic ACTH secretion [38, 53, 54]. The patient 
should be fasting and lying in bed. A venous catheter 
should be inserted the night before the test. The ovine 
CRH is administered at a dosage of 1 μg/kg (max. 100 
μg) of body weight at 08:00. Samples for cortisol and 
ACTH are taken 5’ before administration, at 0’, and 15’, 
30’, and 45’ after the administration of oCRH.
The criterion for diagnosis of CD is a mean increase 
of 20% above baseline for cortisol values 30’ and 45’ 
and an increase in the mean ACTH concentrations of 
at least 35% over basal value 15’ and 30’ after oCRH 
administration [6, 35]. 
In CRH test, 85% of patients with CD respond to 
oCRH with increased plasma ACTH and cortisol pro-
duction. The response to oCRH is not observed in 95% 
of patients with ectopic ACTH production [6,38].
Results of oCRH test and HDDST (Liddle or over-
night) taken together give the diagnostic accuracy of 
98% [6].
LDDS-CRH test
The diagnostic power of the LDDST and the oCRH 
test is enhanced when both tests are combined (the 
test enables also differentiation between CS and pseu-
do-Cushing syndrome more accurately).
The test is performed by intravenous CRH adminis-
tration (1 μg/kg, max 100 μg) 2 h after the last dose of Dx 
in LDDST (LDDST described above) [55]. Adrenocorti-
cotropic hormone and cortisol serum concentrations are 
measured at baseline (–15’, –5’, and 0’) and 15’ after the 
administration of oCRH. In the case of pseudo-Cushing 
syndrome, basal plasma cortisol is low or undetectable 
and there is no response to oCRH.
According to analysis by Martin et al., the sensitiv-
ity of the LDDST-CRH test is 100% and the specificity 
is 67% [56]. Obesity can confound the results of this 
test [57].
Imaging
Magnetic resonance imaging (MRI) is considered to be 
the imaging method of choice for detecting ACTH-se-
creting adenomas [58]. It should be done only after 
biochemical confirmation of ACTH-dependent CS [59]. 
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Detection of pituitary adenoma, on the basis of four 
large paediatric studies (groups from 21 to 72 children 
with CD), is 43–72% [14, 29, 32, 35]. Similarly, the detec-
tion rate of pituitary corticotroph adenomas in adults 
is documented to be 50–70% [60–62].
Pituitary adenomas are generally hypointense com-
pared with the adjacent gland and take up contrast less 
avidly and in a more delayed fashion, and therefore 
fail to enhance with gadolinium [30] (Fig. 3). The poor 
visualisation rate can be explained by the limited spa-
tial resolution of MRI, i.e. small lesions within a small 
pituitary gland are less conspicuous [30]. Spoiled 
gradient-recalled acquisition in the steady-state (SPGR) 
with improved spatial resolution is a newer technique 
in MRI considered better than the conventional 
T-1-weighted spin echo (SE) technique in identifying 
pituitary tumours [59]. 
Studies on the adult population reported that locali-
sation of a tumour in preoperative imaging significantly 
raises the cure rate for CD: by up to 90% (if MRI detects 
pituitary tumor) vs. 50–70% when there is no tumour in 
MRI [63–65]. According to the Consensus Statement on 
Diagnosis and Complications of Cushing’s Syndrome, 
finding a pituitary lesion > 6 mm is regarded as a cut-off 
that can be considered as a corticotroph adenoma [34]. 
In the presence of dynamic biochemical studies com-
patible with CD the size of 6 mm provides a definitive 
diagnosis and does not require further evaluation [34, 
58]. However, the size of pituitary adenoma detected 
in MRI in children is usually less than 6 mm [36], and 
their size at surgery turns out to be even less (≤ 2 mm) 
[12]. Pituitary macroadenomas are extremely rare in 
children [66]. Furthermore, distinguishing a cortico-
troph adenoma and an incidentaloma on the basis of 
the lesion size in MRI has not been confirmed in the 
studies [67, 68]
Bilateral simultaneous inferior petrosal sinus  
sampling
Bilateral simultaneous inferior petrosal sinus sampling 
(BSIPSS) enables distinction between CD and ectopic 
ACTH syndrome and helps to localise the microadeno-
ma within the pituitary gland. If the test is performed 
in an experienced centre, the distinction between CD 
and ectopic ACTH syndrome is nearly 100% [37]. Storr 
et al., in their analysis of 41 children with CD, reported 
that the cure rate in patients who underwent BSIPSS 
preoperatively was higher (73%, 24/33) than in those 
who did not undergo the procedure, although this was 
not statistically significant (p < 0.5) [14].
Bilateral simultaneous inferior petrosal sinus sam-
pling is routinely performed in adult practice when 
the MRI does not show unequivocally a pituitary 
adenoma [30]. Bilateral simultaneous inferior petrosal 
sinus sampling is a highly specialised technique and 
should be performed by experienced interventional 
neuroradiologists with a team of trained operators 
[30, 69]. In the majority of cases, general anaesthesia 
(GA) is not required; however, in young children GA 
may be necessary [30, 70]. In the study by Dias et al. 
children with GA were aged 5.6 and 6.6 years, and 
BSIPSS, despite GA, gave valid results [70].
The test is done by blood sampling from each infe-
rior petrosal sinus for measurement of ACTH concentra-
tion simultaneously with peripheral venous sampling. 
The sampling is performed through catheters inserted 
into the femoral vein and advanced to the petrosal si-
nuses under fluoroscopic guidance. ACTH is measured 
at baseline and at 3’, 5’, and 10’ after oCRH administra-
tion (1 μg/kg, max 100 μg). Because it has been shown 
that each patient could have in one petrosal sinus (left 
or right) a much higher percentage of total ACTH [71], 
blood samples must be taken from both inferior petro-
sal sinuses to avoid making an erroneous diagnosis of 
ectopic ACTH secretion [69].
Interpretation of the test consists of calculating of 
the ratio of ACTH concentration in the sinus (central) 
and the peripheral sample [37]. Patients with CD have 
central-to-peripheral maximal gradient ≥ 2 at baseline 
or central-to-peripheral gradient ≥ 3 at any time point 
after stimulation with oCRH, while no gradient be-
tween the sinus and peripheral sample is observed in 
ectopic ACTH secretion [37]. Lateralisation of ACTH 
Figure 3. MRI scan showing pituitary adenoma. Sagittal plane. 
SE T1-weighted image after contrast injection
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secretion is defined as an interpetrosal sinus ACTH 
gradient (IPSG) of > 1.4. IPSG is calculated by dividing 
the highest IPS ACTH value (right or left) by the value 
at the same time in the contralateral IPS. An IPSG < 1.4 
suggests a midline lesion [72].
The use of BSIPSS for the localisation of pitu-
itary microadenoma to the right or left side of the 
pituitary gland is controversial [72]. The accuracy of 
lateralisation results after CRH stimulation in a large 
meta-analysis was 78% [73]. The published data of 
the results in children are limited. The available data 
show that BSIPSS has been used to predict the side of 
microadenoma with varying results. Batista et al. have 
recently reported in their large analysis of 94 children 
that localisation of a microadenoma by BSIPSS agreed 
with surgical location in only 58% of cases [74]. Having 
excluded 22 lesions that were either centrally located 
or bilateral, the percentage of predictive lateralisation 
increased to 70% [74]. In contrast to this result, four 
other analyses of smaller groups [30, 69, 75, 76]: 41, 27, 
11, and 17 children, stated that ACTH sampling gives 
a better prediction of the site of the microadenoma 
than that by pituitary MR imaging. The first one [30] 
showed that BSIPSS correctly predicted the tumour 
position in all (4) cases; in the second [75] and third 
[76] research there was concordance between the 
BSIPSS finding and the position of the microadenoma 
at surgery in, respectively, 81% (17/21) and 91% (10/11) 
patients. The last study reported that in 91% of pa-
tients BSIPSS showed the correct position of pituitary 
adenoma [70].
The accuracy of the test may be limited by some 
factors: 1. duration of hypercortisolaemia (the sup-
pression of normal corticotrophs by longstanding 
hypercortisolaemia confirms that any ACTH measured 
is secreted by tumour tissue [pituitary or ectopic]) [68]; 
2. different anatomical variants (when venous drainage 
of the pituitary gland does not follow the expected 
normal anatomy, the results are inaccurate) [37]; and 
3. an ectopic CRH-producing tumour [37].
Differences between Cushing’s syndrome 
in children and adults
Standards of procedure for diagnosis and treatment are 
mainly based on experience from the adult population, 
whereas it should be noted that there are some differ-
ences in presentation of the disease and in response 
to treatment [14]. CD in developmental age is distin-
guished by: increased frequency of prepubertal CD 
in males, the different clinical presentation (as shown 
above), the decreased presence of macroadenomas, 
and the frequent absence of radiological evidence of 
an adenoma on MRI [14].
Conclusions and perspectives  
for the future
Recent advances in the medical diagnosis of CD and 
close cooperation with adult endocrinologists have 
improved the medical care of this challenging disease. 
More and more is known about the pathogenesis of 
CD; however, further broadening of current knowledge 
about molecular pathogenesis of CD is of foremost 
importance because it could lead to new treatment 
targets in the future.
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